TRANSCODE THERAPEUTICS INC (RNAZ) Stock Earnings & Estimates
USA - NASDAQ:RNAZ - US89357L5012 - Common Stock
10.95 USD
-0.98 (-8.21%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A -100.00% | N/A | N/A 180.81% | N/A 86.69% | ||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | -6.109M | -18.535M -203.43% | -19.295M -4.10% | -15.126M 21.61% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -384K | -456.9K -18.98% | -726.6K -59.03% | -6.151M -746.56% | -18.634M -202.93% | -19.419M -4.21% | -15.661M 19.35% | N/A 21.84% | N/A -36.67% | N/A -39.63% | N/A -14.41% | N/A 6.11% | N/A 42.28% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A -61.45% | N/A 79.22% | -1,462.72 99.30% | N/A 99.70% | N/A 92.68% | N/A 25.00% | N/A -158.33% | N/A 6.45% | N/A 41.38% |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -1.04 99.30% | -0.80 99.47% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -3.162M -46.02% | -3.468M 31.90% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | -150.64 99.29% | -91.68 | -58.96 | -64.31% |
| Q3 2024 Q2Q % growth | -147.84 99.76% | -461.82 | 313.98 | 67.99% |
| Q2 2024 Q2Q % growth | -665.28 99.45% | -546.64 | -118.64 | -21.70% |
| Q1 2024 Q2Q % growth | -498.96 | -659.74 | 160.78 | 24.37% |
| Q4 2023 Q2Q % growth | -21,104.16 92.86% | -10,178.78 | -10,925.38 | -107.33% |
| Q3 2023 Q2Q % growth | -62,092.80 74.55% | -56,548.80 | -5,544.00 | -9.80% |
| Q2 2023 Q2Q % growth | -121,598.40 54.31% | -127,800.29 | 6,201.89 | 4.85% |
| Q4 2022 Q2Q % growth | -295,680.00 -73.91% | -286,513.92 | -9,166.08 | -3.20% |
| Q3 2022 Q2Q % growth | -243,936.00 -121,967,900.00% | -301,593.60 | 57,657.60 | 19.12% |
| Q2 2022 Q2Q % growth | -266,112.00 | -226,195.20 | -39,916.80 | -17.65% |
| Q4 2021 Q2Q % growth | -170,016.00 | -188,496.00 | 18,480.00 | 9.80% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | 306K | -306K | -100.00% | |
| Q3 2024 Q2Q % growth | 306K | -306K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |